Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
05:20pm, Friday, 29'th May 2026
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily pay
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
04:45pm, Tuesday, 19'th May 2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical comp
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
08:30am, Monday, 18'th May 2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
04:10pm, Thursday, 14'th May 2026
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 mil
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 13'th May 2026
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position i
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
04:01pm, Wednesday, 06'th May 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
08:30am, Monday, 04'th May 2026
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
08:30am, Tuesday, 21'st Apr 2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
04:05pm, Tuesday, 31'st Mar 2026
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the clos
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 25'th Mar 2026
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Ap
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
08:30am, Wednesday, 18'th Mar 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
02:55am, Wednesday, 11'th Mar 2026
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.18 and traded as
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cypr
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cypr
